-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written byWang CongEditorWang Duoyu TypesettingShui Chengwen
A few days ago, mRNA vaccine giant BioNTech founders Uğur Şahin and Özlem Türeci In an interview with BBC, the couple said that BioNTech has made a breakthrough in mRNA cancer vaccines, which makes them optimistic about cancer vaccines in the next few years, and mRNA cancer vaccines are expected to be available
before 2030.
In 2008, Uğur Şahin with his wife Özlem Türeci and his mentor Christoph Huber Co-founded BioNTech
.
Since its inception, BioNTech has been committed to developing mRNA vaccines
.
In 2018, BioNTech partnered with pharmaceutical giant Pfizer to develop a flu vaccine
based on mRNA technology.
Sanofi has also invested in BioNTech twice to obtain the rights to
use its mRNA cancer vaccine in the future.
But more than a decade after its founding, BioNTech is still a niche company and not well known
to the outside world.
The novel coronavirus epidemic at the end of 2020 became a turning point for BioNTech, which timely adjusted its research and development focus and applied its mRNA technology that it had developed for many years to the new coronavirus vaccine
。 As we all know, the new crown mRNA vaccine BNT162b2 developed by it became the first new crown vaccine to enter clinical trials, the first new crown vaccine to receive FDA emergency use authorization on December 11, 2020, and the first new crown vaccine
officially approved by the FDA on August 23, 2021.
The success of the mRNA vaccine has made mRNA technology and BioNTech famous
.
According to BioNTech co-founder and CMO Özlem Türeci, the success of the mRNA vaccine has given back to the company's mRNA cancer vaccine research
.
BioNTech's mRNA new crown vaccine is a full-length mRNA that uses lipid nanoparticles (LNP) as a carrier to deliver the spike protein of the new coronavirus, and after entering human cells, the new crown spike protein expressed by mRNA will be detected by the human immune system.
This produces neutralizing antibodies against the new coronavirus and resists the new coronavirus
that may invade in the future.
Similarly, this mRNA technology can be used to train immune cells to recognize proteins in cancer cells and destroy them
.
In the field of mRNA cancer vaccines, BioNTech is in the leading position, and several mRNA cancer vaccines are in the clinical trial stage
.
BioNTech's mRNA cancer vaccine portfolio includes bowel, skin, lung, head and neck, prostate and ovarian cancers, some of which have been in Phase 2 clinical trials
.
When asked by the BBC when mRNA cancer vaccines will be used in cancer patients, Uğur Şahin, founder and CEO of BioNTech, said that based on the breakthroughs BioNTech has made in the field of mRNA cancer vaccines, he is optimistic about cancer vaccines in the next few years mRNA cancer vaccines are expected to be available by 2030
.
Özlem Türeci, co-founder and CMO of BioNTech, is cautious, saying that as scientists, we cannot easily "cure" cancer, but we have made many breakthroughs and will continue to work hard
.
If medical regulators use the approval process for the new crown vaccine, the mRNA cancer vaccine could be available to cancer patients by 2030
.
Asked about Moderna's accusations in August of BioNTech and Pfizer of infringing on its mRNA vaccine patent, Uğur Şahin said that BioNTech's technology is original, the team spent 20 years developing mRNA technology, and the company will also fight
its own intellectual property.
BioNTech has a wide R&D pipeline, and there are currently four types
: mRNA therapy, cell therapy, monoclonal antibodies and small molecule immunomodulators.
In mRNA therapy, in addition to the approved new crown mRNA vaccines, there are 14 mRNA cancer vaccines in the clinical trial stage, of which 4 are in the phase 2 clinical stage
.
In addition, there are a number of R&D pipelines for infectious diseases such as influenza, tuberculosis, shingles, malaria, and AIDS
.
In September, BioNTech unveiled its CAR-T+CARVac combination therapy for Claudin6 (CLDN6) at the Congress of the European Society of Oncology (ESCO).
Phase 1/2 clinical preliminary data of positive solid tumors (testicular cancer, ovarian cancer, etc.
), which is also the first human trial
to improve the expansion and persistence of CAR-T cells by mRNA vaccine.
The results showed that in the 21 patients that could be assessed, the objective response rate was 33% and the disease control rate was 67%.
It is worth mentioning that the treatment effect of the therapy on 7 testicular cancer patients is encouraging, of which 1 is in complete remission, 3 are in partial remission, and 2 are in stable
condition.
The objective response rate was 57% and the disease control rate was 85%.
As early as July 2020, BioNTech published a paper in the journal Nature announcing the results of a phase 1 clinical trial of its mRNA cancer vaccine BNT111 in the treatment of advanced melanoma, BNT111 Codes 4 tumor-associated antigens that occur in more than 90% of melanoma patients NY-ESO-1, MAGE-A3, tyrosinase and TPTE, clinical trial results showed good safety and preliminary anti-tumor effects
.
Currently, the BNT111 vaccine is currently undergoing phase 2 clinical trials for the treatment of PD-1 inhibitor-refractory/recurrent unresectable stage III or IV melanoma
.
BNT111 received U.
S.
FDA ORPHAN DRUG DESIGNATION in September 2021 and FDA Fast Track designation
in November 2021.
In the years of the pandemic, mRNA vaccine development companies BioNTech and Moderna earned tens of billions of dollars in cash
.
But with most people already vaccinated or even booster shots, and now the Omicron epidemic is much less virulent, the demand for a new crown vaccine will also drop
dramatically.
As a result, revenues for COVID-19 vaccine development companies such as BioNTech and Moderna will also decline
significantly in the coming years.
So far, BioNTech and Moderna, the two mRNA vaccine giants, have only approved new crown mRNA vaccines for marketing
.
In the post-Covid era, how to ensure income has become a top
priority.
Both companies have chosen mRNA cancer vaccines as a top priority for the future
.
Just a few days ago, Moderna announced a joint development and commercialization
of an mRNA cancer vaccine with Merck.
Reference:
style="letter-spacing: 0.
544px;text-align: left;background-color: rgb(255, 255, 255);font-family: -apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;color: rgb(136, 136, 136);font-size: 12px;" _mstmutation="1" _istranslated="1"> style="letter-spacing: 0.
544px;text-align: left;background-color: rgb(255, 255, 255);font-family: -apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;color: rgb(136, 136, 136);font-size: 12px;" _mstmutation="1" _istranslated="1">
Open reprint welcome to forward to Moments and WeChat groups
A few days ago, mRNA vaccine giant BioNTech founders Uğur Şahin and Özlem Türeci In an interview with BBC, the couple said that BioNTech has made a breakthrough in mRNA cancer vaccines, which makes them optimistic about cancer vaccines in the next few years, and mRNA cancer vaccines are expected to be available
before 2030.
In 2008, Uğur Şahin with his wife Özlem Türeci and his mentor Christoph Huber Co-founded BioNTech
.
Since its inception, BioNTech has been committed to developing mRNA vaccines
.
In 2018, BioNTech partnered with pharmaceutical giant Pfizer to develop a flu vaccine
based on mRNA technology.
Sanofi has also invested in BioNTech twice to obtain the rights to
use its mRNA cancer vaccine in the future.
But more than a decade after its founding, BioNTech is still a niche company and not well known
to the outside world.
The novel coronavirus epidemic at the end of 2020 became a turning point for BioNTech, which timely adjusted its research and development focus and applied its mRNA technology that it had developed for many years to the new coronavirus vaccine
。 As we all know, the new crown mRNA vaccine BNT162b2 developed by it became the first new crown vaccine to enter clinical trials, the first new crown vaccine to receive FDA emergency use authorization on December 11, 2020, and the first new crown vaccine
officially approved by the FDA on August 23, 2021.
The success of the mRNA vaccine has made mRNA technology and BioNTech famous
.
According to BioNTech co-founder and CMO Özlem Türeci, the success of the mRNA vaccine has given back to the company's mRNA cancer vaccine research
.
BioNTech's mRNA new crown vaccine is a full-length mRNA that uses lipid nanoparticles (LNP) as a carrier to deliver the spike protein of the new coronavirus, and after entering human cells, the new crown spike protein expressed by mRNA will be detected by the human immune system.
This produces neutralizing antibodies against the new coronavirus and resists the new coronavirus
that may invade in the future.
Similarly, this mRNA technology can be used to train immune cells to recognize proteins in cancer cells and destroy them
.
In the field of mRNA cancer vaccines, BioNTech is in the leading position, and several mRNA cancer vaccines are in the clinical trial stage
.
BioNTech's mRNA cancer vaccine portfolio includes bowel, skin, lung, head and neck, prostate and ovarian cancers, some of which have been in Phase 2 clinical trials
.
When asked by the BBC when mRNA cancer vaccines will be used in cancer patients, Uğur Şahin, founder and CEO of BioNTech, said that based on the breakthroughs BioNTech has made in the field of mRNA cancer vaccines, he is optimistic about cancer vaccines in the next few years mRNA cancer vaccines are expected to be available by 2030
.
Özlem Türeci, co-founder and CMO of BioNTech, is cautious, saying that as scientists, we cannot easily "cure" cancer, but we have made many breakthroughs and will continue to work hard
.
If medical regulators use the approval process for the new crown vaccine, the mRNA cancer vaccine could be available to cancer patients by 2030
.
Asked about Moderna's accusations in August of BioNTech and Pfizer of infringing on its mRNA vaccine patent, Uğur Şahin said that BioNTech's technology is original, the team spent 20 years developing mRNA technology, and the company will also fight
its own intellectual property.
BioNTech has a wide R&D pipeline, and there are currently four types
: mRNA therapy, cell therapy, monoclonal antibodies and small molecule immunomodulators.
In mRNA therapy, in addition to the approved new crown mRNA vaccines, there are 14 mRNA cancer vaccines in the clinical trial stage, of which 4 are in the phase 2 clinical stage
.
In addition, there are a number of R&D pipelines for infectious diseases such as influenza, tuberculosis, shingles, malaria, and AIDS
.
In September, BioNTech unveiled its CAR-T+CARVac combination therapy for Claudin6 (CLDN6) at the Congress of the European Society of Oncology (ESCO).
Phase 1/2 clinical preliminary data of positive solid tumors (testicular cancer, ovarian cancer, etc.
), which is also the first human trial
to improve the expansion and persistence of CAR-T cells by mRNA vaccine.
The results showed that in the 21 patients that could be assessed, the objective response rate was 33% and the disease control rate was 67%.
It is worth mentioning that the treatment effect of the therapy on 7 testicular cancer patients is encouraging, of which 1 is in complete remission, 3 are in partial remission, and 2 are in stable
condition.
The objective response rate was 57% and the disease control rate was 85%.
As early as July 2020, BioNTech published a paper in the journal Nature announcing the results of a phase 1 clinical trial of its mRNA cancer vaccine BNT111 in the treatment of advanced melanoma, BNT111 Codes 4 tumor-associated antigens that occur in more than 90% of melanoma patients NY-ESO-1, MAGE-A3, tyrosinase and TPTE, clinical trial results showed good safety and preliminary anti-tumor effects
.
Currently, the BNT111 vaccine is currently undergoing phase 2 clinical trials for the treatment of PD-1 inhibitor-refractory/recurrent unresectable stage III or IV melanoma
.
BNT111 received U.
S.
FDA ORPHAN DRUG DESIGNATION in September 2021 and FDA Fast Track designation
in November 2021.
In the years of the pandemic, mRNA vaccine development companies BioNTech and Moderna earned tens of billions of dollars in cash
.
But with most people already vaccinated or even booster shots, and now the Omicron epidemic is much less virulent, the demand for a new crown vaccine will also drop
dramatically.
As a result, revenues for COVID-19 vaccine development companies such as BioNTech and Moderna will also decline
significantly in the coming years.
So far, BioNTech and Moderna, the two mRNA vaccine giants, have only approved new crown mRNA vaccines for marketing
.
In the post-Covid era, how to ensure income has become a top
priority.
Both companies have chosen mRNA cancer vaccines as a top priority for the future
.
Just a few days ago, Moderna announced a joint development and commercialization
of an mRNA cancer vaccine with Merck.
Reference:
style="letter-spacing: 0.
544px;text-align: left;background-color: rgb(255, 255, 255);font-family: -apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;color: rgb(136, 136, 136);font-size: 12px;" _mstmutation="1" _istranslated="1"> style="letter-spacing: 0.
544px;text-align: left;background-color: rgb(255, 255, 255);font-family: -apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;color: rgb(136, 136, 136);font-size: 12px;" _mstmutation="1" _istranslated="1">
Open reprint welcome to forward to Moments and WeChat groups
